Latest Breaking News On - Scientific session - Page 4 : comparemela.com

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension ...

SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten

A Former Cyber Spy Raised $30 Million For A Security Startup. Plus: These Are The Richest Women In The World

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM , the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy , at the 73rd Annual.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

/PRNewswire/ Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology.

Lp(a) Tied to Higher CVD Events; Risk Reduction With IPE

New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.